(Q36292132)

13 August 2017

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications (English)

1 reference

13 August 2017

0 references

Viviani S

1

1 reference

13 August 2017

Camerini E

2

1 reference

13 August 2017

Bonfante V

3

1 reference

13 August 2017

Santoro A

4

1 reference

13 August 2017

Balzarotti M

5

1 reference

13 August 2017

Fornier M

6

1 reference

13 August 2017

Devizzi L

7

1 reference

13 August 2017

Verderio P

8

1 reference

13 August 2017

Valagussa P

9

1 reference

13 August 2017

Bonadonna G

10

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

British Journal of Cancer

13 August 2017

1 reference

13 August 2017

77

1 reference

13 August 2017

6

1 reference

13 August 2017

992-997

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.163

13 August 2017

0 references

cites work

Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Serum concentrations of cytokines in patients with Hodgkin's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

The immune derangement in Hodgkin's disease.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Production of tumor necrosis factor-alpha and lymphotoxin by cells of Hodgkin's neoplastic cell lines HDLM-1 and KM-H2

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

30 September 2017

Interleukin 6 (IL-6).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

The soluble interleukin-2 receptor: biology, function, and clinical application

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Biological properties of interleukin 10.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Interleukin 12: a new clinical player in cytokine therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

The released interleukin 2 receptor binds interleukin 2 efficiently

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Flexible regression models with cubic splines

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Tumor necrosis factor alpha and lymphotoxin production in Hodgkin's disease

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150083

Serum cytokine levels correlate with clinical parameters in Hodgkin's disease

29 June 2018

1 reference

12 December 2020

Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study

1 reference

12 December 2020

Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic, and phenotypic features

1 reference

12 December 2020

Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis

1 reference

12 December 2020

Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma

1 reference

12 December 2020

Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of a poor prognosis in adult Hodgkin's disease

1 reference

12 December 2020

Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer

1 reference

12 December 2020

Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients

1 reference

12 December 2020

Tumor burden as the most important prognostic factor in early stage Hodgkin's disease.Relations to other prognostic factors and implications for choice of treatment

1 reference

12 December 2020

Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease

1 reference

12 December 2020

Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.163

1 reference

13 August 2017

1 reference

13 August 2017

1 reference